Pascal Breton (PhD) President and Managing Director
With a PhD from the University of Orleans (1989) and having spent 3 years at the National Institute of Health (NIH, USA), Dr. Pascal Breton boasts a combined international experience spanning 20 years working in pharmaceutical and biotechnology companies. A project manager for UPSA Laboratories (Bristol Myers Squibb), he pursued his career with the Halisol group, which was founded by Dr. Nicole Bru (former owner and president of UPSA laboratories). There, he cofounded and ran the Virsol company, which is dedicated to the development of new biomaterials that enable the administration and targeting of active principles. While still at Halisol, he served as Investment Director for biotechnologies and was also a board member in several companies such as Conjuchem Inc. (Montreal), Rimon Therapeutics Ltd. (Toronto), BagTech Corp. (Montreal) and Aarmedis Corp. (Baltimore).
He was successively a business development manager and project manager for the development of MEPACT®/Junovan® (cancer drug developed by IDM S.A., a subsidiary of IDM Pharma Inc., NASDAQ: IDMI) and Director of Global Biotech Key Accounts at SGS Life Science Services. He has therefore consolidated his expertise in the biotechnology sector.
As of 2009, he is President and Managing Director of VitamFero, which he co-founded in 2003 with Edouard Sèche.
Sophie Barreteau (PhD) Director in charge of industrial research
Didier Roy Development Director
In addition to an Analytical Engineering degree and an MBA from Paris I Panthéon Sorbonne, Didier Roy also has over 25 years experience in the pharmaceutical and biopharmaceutical industry. He began his career in 1988, in the UPSA laboratories' Pre-formulation department, where he was in charge of the development of innovative pharmaceutical forms. In the late 90s he joined the Virsol company. Successively Head of Development and Executive Director, he then took over biomaterial development operations (for both pharmaceutical uses and medical devices). In particular, he developed a wound suture product that is currently being patented in the United States. More recently, as Scientific Director within the Halisol Group he completed his international experience by managing a Life Sciences investment portfolio whose assets are based in Europe and North America. Among other things, he organised the sale of one of the group's subsidiaries' assets and secured the transfer of the associated technologies. Didier Roy joined VitamFero in 2012, taking over all of its pharmaceutical development activities.
The VitamFero team
A young and dynamic team that is determined to provide solutions to today's sanitary safety challenges